Af­ter a slap­down on Orkam­bi price, Ver­tex is drop­ping French tri­al sites while warn­ing pa­tients on ac­cess

Ver­tex Phar­ma $VRTX is play­ing hard­ball with French drug reg­u­la­tors — and cys­tic fi­bro­sis pa­tients wait­ing for their next-gen triple are get­ting caught in the mid­dle.

Mired in a long-run­ning dis­pute over the re­im­burse­ment lev­el for their drug Orkam­bi, Ver­tex has de­cid­ed to shut out the tri­al sites it had se­lect­ed in France for the late-stage com­bi­na­tion stud­ies for its cys­tic fi­bro­sis drugs, in­clud­ing the ex­per­i­men­tal VX-659, which has raised hopes for a broad swath of pa­tients.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN